Scholars Central

Conference abstractPublished 9 May 2016

Unclassifiable high grade B-cell lymphomas with overlapping features

Authors: Jessica A Hemminger

The Ohio State University Wexner Medical Center, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The 2008 World Health Organization (WHO) classification of lymphomas include two gray zone categories: B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (CHL) (BCLU-DLBCL/CHL) and B-cell lymphoma, unclassifiable with features intermediate between DLBCL and Burkitt lymphoma (BL) (BCLU-DLBCL/BL). BCLU-DLBCL/CHL demonstrates overlapping clinical, morphologic and immunophenotypic features between DLBCL and CHL and are frequently referred to as gray zone lymphomas. Many of these lymphomas occur in the mediastinum and show features intermediate between CHL and the DLBCL subtype primary mediastinal large B-cell lymphoma (PMBL). However, non-mediastinal BCLU-DLBCL/CHL also occurs. Rare instances of composite lymphoma with CHL and PMBL as well as synchronous and metachronous cases are also recognized. Immunophenotypically, the B-cell program is usually preserved but is accompanied by expression of CHL markers. The optimal therapeutic approach has yet to be established; however, studies have suggested treatment regimens used for non-Hodgkin B-cell lymphomas are more effective. BCLU-DLBCL/BL has morphologic, immunophenotypic and molecular features that overlap between DLBCL and BL. High grade B-cell lymphomas that harbor translocations involving MYC and BCL2 and/or BCL6, so-called double-hit and triple-hit lymphomas are commonly classified as BCLU-DLBCL/BL. Similarly, high grade lymphomas with MYC and BCL2 overexpression, as determined by immunohistochemistry (double-expressor large B-cell lymphomas), are also frequently placed in this WHO category. BCLU-DLBCL/BL are typically aggressive lymphomas and many are resistant to current therapies.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectHaematology
  • BylineArticles whose byline prints “Jessica A Hemminger”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels